CRANBURY, N.J., Sept. 23, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that a review of the neurobiology and treatment efficacy of bremelanotide for hypoactive sexual desire disorder (“HSDD”) was presented at the International Society for Sexual Medicine 20th World Meeting in Beijing, China.
Anita H. Clayton, M.D., of the University of Virginia School of Medicine, is lead author on the poster entitled “Bremelanotide: A Review of Its Neurobiology and Treatment Efficacy for HSDD.” The poster addresses mechanisms of sexual response and the pathophysiology of HSDD, and describes the potential of bremelanotide to modulate brain pathways involved in sexual response. The poster is available at Palatin’s website, www.palatin.com.
James G. Pfaus, Ph.D., of Concordia University in Montreal, Canada was co-author, together with Johna Lucas, M.D., Carl Spana, Ph.D. and Robert Jordan of Palatin.
Palatin is developing bremelanotide, a centrally-mediated medication, as a subcutaneous, on-demand treatment for premenopausal women diagnosed with HSDD. Bremelanotide, which is a melanocortin 4 receptor agonist drug candidate, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone).
Last patient visits for the efficacy portion of Phase 3 trials with bremelanotide for HSDD were completed in the third quarter of calendar year 2016. Topline results are projected to be released early fourth quarter of calendar year 2016.
Bremelanotide is dosed as an as-needed (not chronic) medical treatment. This treatment is unlike flibanserin (ADDYI®) and some other female sexual dysfunction treatments in development that require daily administration and life style modifications.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at www.Palatin.com.
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin’s ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin’s products, and other factors discussed in Palatin’s periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.
SOURCE Palatin Technologies, Inc.